POMDOCTOR LIMITED
NNASDAQ:POMRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- POMDOCTOR Ltd (POM) operates an online medical services platform specializing in chronic disease management and pharmaceutical services in China. The company offers a one-stop platform that organically connects patients to doctors and pharmaceutical products through its two primary segments: Internet hospital, which provides online consultations, prescription renewals, and chronic disease management (CDM) services; and pharmaceutical supply chain, which delivers supply chain management and platform operation services to other pharmaceutical platforms, with the majority of revenue derived from this segment. Founded in 2015 and headquartered at No.19-23 Hejing Road, Dongsha Street, Yongxu Industrial Park, Liwan District, Guangzhou, China, POMDOCTOR serves patients, pharmacies, suppliers, and medical professionals across the country, targeting chronic disease patients in the healthcare technology sector. In recent developments, the company completed its initial public offering on Nasdaq in October 2025, raising approximately $20 million in gross proceeds from 5,000,004 American Depositary Shares priced at $4.00 each, with an option for underwriter Joseph Stone Capital to purchase up to 750,000 additional ADSs; strengthened collaborations with pharmaceutical manufacturers, driving an 83.2% increase in online pharmacy sales to RMB66.4 million (US$9.3 million) in the first half of fiscal 2025 ended June 30, 2025; and reported overall net revenue growth of 16.2% for the same period, bolstered by higher service fees to partner doctors and adaptation to China's evolving healthcare landscape.
Company News
POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq
POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare
POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination
POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization
POMDOCTOR LIMITED Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure Model
POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy
POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine
POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure
POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities
POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare
POMDOCTOR LIMITED Announces Strategic Upgrade Toward Infrastructure for Predictive Healthcare Data and Services
POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026
Aisan Adopts Celanese POM ECO-C for Fuel Pump Modules Supplied to a North American Automaker
POMDOCTOR LIMITED Announces Plan to Implement ADS Ratio Change
POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results
POM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 13 Deadline in Securities Class Action - POM
POM CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds PomDoctor Investors of Securities Class Action Deadline on April 13, 2026
POM Deadline: POM Investors with Losses in Excess of $100K Have Opportunity to Lead PomDoctor Ltd. Securities Fraud Lawsuit